Our vision is to create the simplest device for the most complex 3D biology. With perfused vessels, co-cultures and optimized microenvironments. And so easy-to-use that you almost forget you’re working with probably the most advanced tissue culture platform ever. With the OrganoPlate®, that vision is now here. Say hello to the OrganoPlate®, the future of 3D tissue models.
We all want better medicines, that’s obvious. To make this possible, we need better disease models, fully human and physiologically relevant. Truly informative tools, compatible with compounds and with high-throughput readout equipment. And of course we need them today, rather than tomorrow. As true pioneers in organ-on-a-chip biology, we are proud to develop any-throughput human tissue and disease models in the OrganoPlate® for the industry.
MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
Mimetas has not received any reviews.
Mimetas has not received any endorsements.